--- title: "Responding to FDA Deficiency Letters | MedTech Cyber Tips" description: "Turn an FDA cybersecurity hold into a clean clearance. This guide provides actionable tips for medical device manufacturers on how to effectively respond to…" lang: en json-ld: | [ { "@context": "https://schema.org", "@graph": [ { "@type": "WebSite", "@id": "https://medtechcybertips.com/#website", "url": "https://medtechcybertips.com/", "name": "MedTech Cyber Tips", "description": "The ultimate organized guide to medical device cybersecurity.", "inLanguage": "en-US", "publisher": { "@id": "https://medtechcybertips.com/#org" }, "potentialAction": { "@type": "SearchAction", "target": "https://medtechcybertips.com/topics?q={search_term_string}", "query-input": "required name=search_term_string" } }, { "@type": "Organization", "@id": "https://medtechcybertips.com/#org", "name": "MedTech Cyber Tips", "url": "https://medtechcybertips.com/", "logo": "https://medtechcybertips.com/icon-512.png", "sponsor": { "@type": "Organization", "name": "Blue Goat Cyber", "url": "https://bluegoatcyber.com", "sameAs": [ "https://home.bluegoatcyber.com/", "https://codebluechart.com/", "https://why.bluegoatcyber.com/", "https://spdf.bluegoatcyber.com/", "https://threatmodel.bluegoatcyber.com/", "https://pentesting.bluegoatcyber.com/", "https://premarket.bluegoatcyber.com/", "https://fdaresponse.bluegoatcyber.com/", "https://postmarket.bluegoatcyber.com/", "https://goatwatch.bluegoatcyber.com/" ] } } ] }, { "@context": "https://schema.org", "@type": "Article", "headline": "Responding to FDA Deficiency Letters", "description": "This guide provides actionable tips for medical device manufacturers on how to effectively respond to FDA cybersecurity deficiency letters and additional information requests, aiming for a cleared submission and market launch without delays.", "image": "https://medtechcybertips.com/og/topics/fdaresponse.png", "datePublished": "2025-01-01", "dateModified": "2026-08-18", "author": { "@type": "Person", "@id": "https://medtechcybertips.com/authors/editorial-team", "name": "MedTech Cyber Tips Editorial Team" }, "reviewedBy": { "@type": "Person", "@id": "https://medtechcybertips.com/authors/editorial-team", "name": "MedTech Cyber Tips Editorial Team" }, "publisher": { "@type": "Organization", "name": "MedTech Cyber Tips", "url": "https://medtechcybertips.com", "sponsor": { "@type": "Organization", "name": "Blue Goat Cyber" } }, "mainEntityOfPage": "https://medtechcybertips.com/topics/fdaresponse", "about": "Submission" }, { "@context": "https://schema.org", "@type": "Person", "@id": "https://medtechcybertips.com/authors/editorial-team", "url": "https://medtechcybertips.com/authors/editorial-team", "name": "MedTech Cyber Tips Editorial Team", "jobTitle": "Medical Device Cybersecurity Editors", "description": "The MedTech Cyber Tips editorial team is a group of practitioners with hands-on experience across FDA premarket cybersecurity submissions, Secure Product Development Framework (SPDF) implementation, medical device threat modeling, and postmarket vulnerability management. Every article, checklist, and update on this site is reviewed for accuracy against the FDA's February 3, 2026 final premarket cybersecurity guidance, Section 524B of the FD&C Act, MDCG 2019-16 Rev.2, IEC 81001-5-1, ISO 14971, and the EU Cyber Resilience Act. The team also tracks 510(k) deficiency patterns and CVE trends affecting connected medical devices so guidance on the site stays current.", "knowsAbout": [ "Medical device cybersecurity", "FDA Section 524B", "FDA premarket cybersecurity guidance (Feb 3, 2026)", "Secure Product Development Framework", "SBOM and VEX", "Medical device threat modeling", "Postmarket vulnerability management", "EU MDR cybersecurity (MDCG 2019-16 Rev.2)", "EU Cyber Resilience Act", "IEC 81001-5-1", "ISO 14971 risk management" ], "sameAs": [ "https://bluegoatcyber.com/about" ], "worksFor": { "@type": "Organization", "name": "MedTech Cyber Tips", "url": "https://medtechcybertips.com/" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://medtechcybertips.com" }, { "@type": "ListItem", "position": 2, "name": "Topics", "item": "https://medtechcybertips.com/topics" }, { "@type": "ListItem", "position": 3, "name": "FDA Response", "item": "https://medtechcybertips.com/topics/fdaresponse" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is an FDA cybersecurity deficiency letter?", "acceptedAnswer": { "@type": "Answer", "text": "A cybersecurity deficiency letter is FDA feedback (typically part of an Additional Information request during 510(k)/De Novo/PMA review) identifying gaps in your cybersecurity submission. It stops the review clock until you provide an adequate response." } }, { "@type": "Question", "name": "How should we respond to an FDA cyber deficiency?", "acceptedAnswer": { "@type": "Answer", "text": "Address every question point-by-point with concrete evidence, not restated claims. Attach updated threat models, SBOM/VEX, test reports, or labeling as appropriate. When you disagree with a finding, provide a rationale grounded in your risk management file rather than pushing back stylistically." } }, { "@type": "Question", "name": "How long do we have to respond to an FDA deficiency?", "acceptedAnswer": { "@type": "Answer", "text": "Typically 180 days for 510(k)/De Novo, though the specific letter will state the deadline. Extensions are possible but require justification and may signal to reviewers that the underlying issue is unresolved." } }, { "@type": "Question", "name": "What are the most common cybersecurity deficiencies FDA cites?", "acceptedAnswer": { "@type": "Answer", "text": "Threat models missing STRIDE coverage per interface, no SBOM or non-machine-readable SBOM, missing VEX, penetration test scope that omits an interface, no coordinated vulnerability disclosure policy, and labeling that omits cybersecurity information required under the 2026 guidance." } }, { "@type": "Question", "name": "Can we call FDA before responding to clarify a deficiency?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. A brief pre-response teleconference through your Regulatory Project Manager (RPM) is often the fastest way to resolve ambiguity, especially on threat-modeling scope or SBOM depth. It costs nothing and typically shortens the overall cycle." } } ] } ] --- [Skip to main content](#main) [ MedTech Cyber Tips The Ultimate Guide ](/) [Home](/)[Find Your Path](/journey)[All Topics](/topics)Reference[About](/about) Search ⌘K [All topics](/topics) Submission # Responding to FDA Deficiency Letters This guide provides actionable tips for medical device manufacturers on how to effectively respond to FDA cybersecurity deficiency letters and additional information requests, aiming for a cleared submission and market launch without delays. For: Medical device manufacturers facing FDA cybersecurity deficiency letters, additional information requests, or full holds. 5 min read Last updated Jul 10, 2026· 1mo ago Print Reviewed by [MedTech Cyber Tips Editorial Team](/authors/editorial-team) · Last reviewed July 2026 FDA deficiency response cadence ### From hold letter to cleared submission Step 1 Receive letter Log clock start; route to PSIRT + RA lead Step 2 Categorize items Split major vs minor; map each to submission section Step 3 Build evidence Updated threat model, SBOM/VEX, test reports, traceability Step 4 Respond on point Line-by-line reply, no scope creep, full re-pagination Major deficiencies typically allow 180 days to respond. Miss it and the submission is withdrawn. 10 structured tips Checklist mode ## The walk-through 01 Strategic ### Understand the FDA Clock and Costs of Delay Copy link Recognize the 180-day FDA response window and the escalating costs of delays, including engineering hours, missed launches, and potential for additional deficiency rounds. 02 Strategic ### Prioritize Prompt Response Copy link Address deficiencies quickly to avoid extended FDA holds, which can lead to significant revenue impact and investor scrutiny. 03 Process ### Thoroughly Review and Analyze Deficiency Letters Copy link Dissect the FDA hold letter line by line to accurately identify specific reviewer requests and the exact evidence needed for a complete response. 04 Documentation ### Craft Precise and Complete Responses to AI Requests Copy link When the FDA requests additional information, provide precise and complete answers that directly address every question without oversharing unnecessary details. 05 Technical ### Remediate and Align Threat Models with FDA Expectations Copy link Rebuild or strengthen flagged threat models to meet FDA expectations, ensuring alignment with AAMI [TIR57](/glossary/tir57) and industry best practices. 06 Technical ### Perform Comprehensive Penetration Testing and Retesting Copy link Conduct or redo penetration testing to address any gaps identified by the FDA, providing clear and reviewer-grade evidence of vulnerability management. 07 Documentation ### Conduct Documentation Gap Analysis Copy link Identify and address missing documentation, such as incomplete SBOMs, SPDFs, or weak risk assessments, and build out the necessary artifacts. 08 Process ### Assemble a Full and Reviewer-Ready Response Package Copy link Compile and format the entire deficiency response package, ensuring it is ready for [eSTAR](/glossary/estar) upload and easy consumption by the FDA reviewer. 09 Compliance ### Ensure Traceability and Alignment with ISO 14971 Copy link Update risk assessments with clear traceability to [ISO 14971](/glossary/iso-14971) and ensure all cybersecurity documentation, including threat models, are connected to patient harm. 10 Documentation ### Include Complete SBOM + VEX with Vulnerability Triage Copy link Provide a comprehensive Software Bill of Materials ([SBOM](/glossary/sbom)) and Vulnerability Exploitability eXchange ([VEX](/glossary/vex)) with evidence of vulnerability triage and remediation documentation. ### Common pitfalls - Submitting a rushed response with templated threat models, incomplete SBOM/VEX, and pen test scope that ignores critical areas (e.g., BLE/cloud) often leads to another deficiency round and prolonged delays. - Failing to provide line-by-line Section 524B traceability in the response will result in reviewer flags. - Having junior authors with no FDA review history prepare the response can lead to rejection and extended hold periods. - Over-sharing information that is not directly requested by the FDA can lead to new questions and further delays. ### Your next steps 1. 1 Schedule a discovery session with cybersecurity experts who specialize in FDA responses to analyze your deficiency letter and develop a response strategy. 2. 2 Immediately begin a detailed gap analysis to determine necessary evidence and documentation updates. 3. 3 Engage experienced MedTech cybersecurity engineers to build required artifacts like updated threat models, SBOM/VEX, and conduct penetration testing. ### Sources & references Authoritative guidance and standards underpinning this topic. Always confirm the latest revision with the publisher. - FDA [Premarket Submission Process - Interactive & Deficiency Reviews](https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/510k-submission-process) - FDA [Cybersecurity Premarket Guidance - Documentation Expectations](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions) ## Frequently asked questions Quick answers to the questions teams most often ask about this topic. ### What is an FDA cybersecurity deficiency letter? A cybersecurity deficiency letter is FDA feedback (typically part of an Additional Information request during 510(k)/De Novo/PMA review) identifying gaps in your cybersecurity submission. It stops the review clock until you provide an adequate response. ### How should we respond to an FDA cyber deficiency? Address every question point-by-point with concrete evidence, not restated claims. Attach updated threat models, SBOM/VEX, test reports, or labeling as appropriate. When you disagree with a finding, provide a rationale grounded in your risk management file rather than pushing back stylistically. ### How long do we have to respond to an FDA deficiency? Typically 180 days for 510(k)/De Novo, though the specific letter will state the deadline. Extensions are possible but require justification and may signal to reviewers that the underlying issue is unresolved. ### What are the most common cybersecurity deficiencies FDA cites? Threat models missing STRIDE coverage per interface, no SBOM or non-machine-readable SBOM, missing VEX, penetration test scope that omits an interface, no coordinated vulnerability disclosure policy, and labeling that omits cybersecurity information required under the 2026 guidance. ### Can we call FDA before responding to clarify a deficiency? Yes. A brief pre-response teleconference through your Regulatory Project Manager (RPM) is often the fastest way to resolve ambiguity, especially on threat-modeling scope or SBOM depth. It costs nothing and typically shortens the overall cycle. Sponsored | how Blue Goat Cyber℠ helps ### Turn an FDA hold into a clean clearance Blue Goat Cyber℠ specializes in rapid response to FDA cybersecurity deficiency letters. Most clients resolve in a single response cycle. Specialists in cyber AI and Refuse to Accept (RTA) responses. [Get help responding to an FDA letter](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) 4.9 / 5 · 15+ client reviews "BlueGoat supported LLA Technologies and the Recordis™ platform through critical cybersecurity testing required for our FDA 510(k) submission. Their work demonstrated technical rigor, a strong understanding of regulatory expectations, and an ability to translate complex findings into meaningful improvements. They maintained excellent communication, managed the engagement professionally, and met all timelines - enabling us to secure certification without delay." Andy Parkins , LLA Technologies (Recordis™) 250+ FDA submissions · 0 rejections Veteran-owned, Scottsdale AZ Exclusively medical device cybersecurity On this page 5 min read - [01 · Understand the FDA Clock and Costs of Delay](#tip-0) - [02 · Prioritize Prompt Response](#tip-1) - [03 · Thoroughly Review and Analyze Deficiency Letters](#tip-2) - [04 · Craft Precise and Complete Responses to AI Requests](#tip-3) - [05 · Remediate and Align Threat Models with FDA Expectations](#tip-4) - [06 · Perform Comprehensive Penetration Testing and Retesting](#tip-5) - [07 · Conduct Documentation Gap Analysis](#tip-6) - [08 · Assemble a Full and Reviewer-Ready Response Package](#tip-7) - [09 · Ensure Traceability and Alignment with ISO 14971](#tip-8) - [10 · Include Complete SBOM + VEX with Vulnerability Triage](#tip-9) - [Common pitfalls](#pitfalls) - [Your next steps](#next-steps) - [FAQ](#faq) Deep dive Hands-on help from Blue Goat Cyber The team behind this guide ships the work - read the canonical service page. [Visit on bluegoatcyber.com](https://bluegoatcyber.com/services/fda-cybersecurity-deficiency-response) Keep going ### Related topics [ Overview Start here. The big picture for MedTech security. Read guide ](/topics/home)[ Premarket Submit a cybersecurity package the FDA will accept. Read guide ](/topics/premarket) Continue by phase Jump to all guides for the lifecycle phase that fits where you are. [Submission](/journey/submission) [All topics](/topics)[ Move to Postmarket Overview Start here. The big picture for MedTech security. ](/topics/home) MedTech Cyber Tips The organized, end-to-end guide to medical device cybersecurity, from concept through postmarket. Part of the Blue Goat Cyber family. Topics - [Overview](/topics/home) - [Why It Matters](/topics/why) - [SPDF](/topics/spdf) - [Threat Modeling](/topics/threatmodel) - [Pentesting](/topics/pentesting) Reference - [Glossary](/glossary) - [FDA vs MDR](/compare) - [Resources](/resources) - [Updates](/updates) - [RSS feed](/rss.xml) © 2026 medtechcybertips.com. An educational resource sponsored by Blue Goat Cyber. Not legal or regulatory advice.